摘要
Objective:To investigate the cost--utility of coronary heart disease percutaneous coronary intervention in 13 cities in China.Methods:(during the first half year of 2006 630 patients undergoing pci were enrolled in this study.life-quality and cost were assessed prospectively for 613 patients over 12-month follow-up period.)the strategy we used was cost-utility analysis.the main outcome was the cost per gained mark of the 36 items short form of health survey(SF-36)and quality adusted life year(QALY)after 9-month of follow-up.Results:The average sore is increased by 20.59,which is statistically significant.the cost-effective analysis indicate that the cost per one incremental mark of SF-36 would be 2611.92 RMB and per QALY would be 78384.91 RMB.Conclusion:Percutaneous intervention therapy is effective for coronary heart disease after 9-month follow-up.this analysis provide an example of how to evaluate cost-utility of percutaneous coronary intervention.the cost per QALY is located in a acceptable range.
Objective:To investigate the cost--utility of coronary heart disease percutaneous coronary intervention in 13 cities in China.Methods:(during the first half year of 2006 630 patients undergoing pci were enrolled in this study.life-quality and cost were assessed prospectively for 613 patients over 12-month follow-up period.)the strategy we used was cost-utility analysis.the main outcome was the cost per gained mark of the 36 items short form of health survey(SF-36)and quality adusted life year(QALY)after 9-month of follow-up.Results:The average sore is increased by 20.59,which is statistically significant.the cost-effective analysis indicate that the cost per one incremental mark of SF-36 would be 2611.92 RMB and per QALY would be 78384.91 RMB.Conclusion:Percutaneous intervention therapy is effective for coronary heart disease after 9-month follow-up.this analysis provide an example of how to evaluate cost-utility of percutaneous coronary intervention.the cost per QALY is located in a acceptable range.
出处
《心肺血管病杂志》
CAS
2010年第S1期78-79,共2页
Journal of Cardiovascular and Pulmonary Diseases